Treatment of collagen-induced arthritis using immune modulatory properties of human mesenchymal stem cells

Kyu Hyung Park, Chin Hee Mun, Mi Il Kang, Sang Won Lee, Soo Kon Lee, YongBeom Park

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) have immune modulatory properties. We investigated the potential therapeutic effects of human bone marrow (BM)-, adipose tissue (AD)-, and cord blood (CB)-derived MSCs in an experimental animal model of rheumatoid arthritis (RA) and explored the mechanism underlying immune modulation by MSCs. We evaluated the therapeutic effect of clinically available human BM-, AD-, and CB-derived MSCs in DBA/1 mice with collagen-induced arthritis (CIA). CIA mice were injected intraperitoneally with three types of MSCs. Treatment control animals were injected with 35 mg/kg methotrexate (MTX) twice weekly. Clinical activity in CIA mice, degree of inflammation, cytokine expression in the joint, serum cytokine levels, and regulatory T cells (Tregs) were evaluated. Mice treated with human BM-, AD-, and CB-MSCs showed significant improvement in clinical joint score, comparable to MTX-treated mice. Histologic examination showed greatly reduced joint inflammation and damage in MSC-treated mice compared with untreated mice. Microcomputed tomography also showed little joint damage in the MSC-treated group. MSCs significantly decreased serum interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, and interferon-γ and increased IL-10 and transforming growth factor-β levels. Tregs were increased in mice treated with MSCs compared to untreated or MTXtreated mice. Human BM-, AD-, and CB-MSCs significantly suppressed joint inflammation in CIA mice. The cells decreased proinflammatory cytokines and upregulated anti-inflammatory cytokines and induced Tregs. Therefore, our study suggests that the use of human BM-, AD-, and CB-MSCs could be an effective therapeutic approach for RA.

Original languageEnglish
Pages (from-to)1057-1072
Number of pages16
JournalCell transplantation
Volume25
Issue number6
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Experimental Arthritis
Stem cells
Mesenchymal Stromal Cells
Collagen
Fetal Blood
Bone
Blood
Joints
Bone Marrow
Cytokines
Therapeutic Uses
Inflammation
Methotrexate
Rheumatoid Arthritis
Animals
Interferons
X-Ray Microtomography
Inbred DBA Mouse
T-cells
Transforming Growth Factors

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Park, Kyu Hyung ; Mun, Chin Hee ; Kang, Mi Il ; Lee, Sang Won ; Lee, Soo Kon ; Park, YongBeom. / Treatment of collagen-induced arthritis using immune modulatory properties of human mesenchymal stem cells. In: Cell transplantation. 2016 ; Vol. 25, No. 6. pp. 1057-1072.
@article{b2d21336ee834297bcb9b40393fd94a2,
title = "Treatment of collagen-induced arthritis using immune modulatory properties of human mesenchymal stem cells",
abstract = "Mesenchymal stem cells (MSCs) have immune modulatory properties. We investigated the potential therapeutic effects of human bone marrow (BM)-, adipose tissue (AD)-, and cord blood (CB)-derived MSCs in an experimental animal model of rheumatoid arthritis (RA) and explored the mechanism underlying immune modulation by MSCs. We evaluated the therapeutic effect of clinically available human BM-, AD-, and CB-derived MSCs in DBA/1 mice with collagen-induced arthritis (CIA). CIA mice were injected intraperitoneally with three types of MSCs. Treatment control animals were injected with 35 mg/kg methotrexate (MTX) twice weekly. Clinical activity in CIA mice, degree of inflammation, cytokine expression in the joint, serum cytokine levels, and regulatory T cells (Tregs) were evaluated. Mice treated with human BM-, AD-, and CB-MSCs showed significant improvement in clinical joint score, comparable to MTX-treated mice. Histologic examination showed greatly reduced joint inflammation and damage in MSC-treated mice compared with untreated mice. Microcomputed tomography also showed little joint damage in the MSC-treated group. MSCs significantly decreased serum interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, and interferon-γ and increased IL-10 and transforming growth factor-β levels. Tregs were increased in mice treated with MSCs compared to untreated or MTXtreated mice. Human BM-, AD-, and CB-MSCs significantly suppressed joint inflammation in CIA mice. The cells decreased proinflammatory cytokines and upregulated anti-inflammatory cytokines and induced Tregs. Therefore, our study suggests that the use of human BM-, AD-, and CB-MSCs could be an effective therapeutic approach for RA.",
author = "Park, {Kyu Hyung} and Mun, {Chin Hee} and Kang, {Mi Il} and Lee, {Sang Won} and Lee, {Soo Kon} and YongBeom Park",
year = "2016",
month = "1",
day = "1",
doi = "10.3727/096368915X687949",
language = "English",
volume = "25",
pages = "1057--1072",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "6",

}

Treatment of collagen-induced arthritis using immune modulatory properties of human mesenchymal stem cells. / Park, Kyu Hyung; Mun, Chin Hee; Kang, Mi Il; Lee, Sang Won; Lee, Soo Kon; Park, YongBeom.

In: Cell transplantation, Vol. 25, No. 6, 01.01.2016, p. 1057-1072.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of collagen-induced arthritis using immune modulatory properties of human mesenchymal stem cells

AU - Park, Kyu Hyung

AU - Mun, Chin Hee

AU - Kang, Mi Il

AU - Lee, Sang Won

AU - Lee, Soo Kon

AU - Park, YongBeom

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Mesenchymal stem cells (MSCs) have immune modulatory properties. We investigated the potential therapeutic effects of human bone marrow (BM)-, adipose tissue (AD)-, and cord blood (CB)-derived MSCs in an experimental animal model of rheumatoid arthritis (RA) and explored the mechanism underlying immune modulation by MSCs. We evaluated the therapeutic effect of clinically available human BM-, AD-, and CB-derived MSCs in DBA/1 mice with collagen-induced arthritis (CIA). CIA mice were injected intraperitoneally with three types of MSCs. Treatment control animals were injected with 35 mg/kg methotrexate (MTX) twice weekly. Clinical activity in CIA mice, degree of inflammation, cytokine expression in the joint, serum cytokine levels, and regulatory T cells (Tregs) were evaluated. Mice treated with human BM-, AD-, and CB-MSCs showed significant improvement in clinical joint score, comparable to MTX-treated mice. Histologic examination showed greatly reduced joint inflammation and damage in MSC-treated mice compared with untreated mice. Microcomputed tomography also showed little joint damage in the MSC-treated group. MSCs significantly decreased serum interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, and interferon-γ and increased IL-10 and transforming growth factor-β levels. Tregs were increased in mice treated with MSCs compared to untreated or MTXtreated mice. Human BM-, AD-, and CB-MSCs significantly suppressed joint inflammation in CIA mice. The cells decreased proinflammatory cytokines and upregulated anti-inflammatory cytokines and induced Tregs. Therefore, our study suggests that the use of human BM-, AD-, and CB-MSCs could be an effective therapeutic approach for RA.

AB - Mesenchymal stem cells (MSCs) have immune modulatory properties. We investigated the potential therapeutic effects of human bone marrow (BM)-, adipose tissue (AD)-, and cord blood (CB)-derived MSCs in an experimental animal model of rheumatoid arthritis (RA) and explored the mechanism underlying immune modulation by MSCs. We evaluated the therapeutic effect of clinically available human BM-, AD-, and CB-derived MSCs in DBA/1 mice with collagen-induced arthritis (CIA). CIA mice were injected intraperitoneally with three types of MSCs. Treatment control animals were injected with 35 mg/kg methotrexate (MTX) twice weekly. Clinical activity in CIA mice, degree of inflammation, cytokine expression in the joint, serum cytokine levels, and regulatory T cells (Tregs) were evaluated. Mice treated with human BM-, AD-, and CB-MSCs showed significant improvement in clinical joint score, comparable to MTX-treated mice. Histologic examination showed greatly reduced joint inflammation and damage in MSC-treated mice compared with untreated mice. Microcomputed tomography also showed little joint damage in the MSC-treated group. MSCs significantly decreased serum interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, and interferon-γ and increased IL-10 and transforming growth factor-β levels. Tregs were increased in mice treated with MSCs compared to untreated or MTXtreated mice. Human BM-, AD-, and CB-MSCs significantly suppressed joint inflammation in CIA mice. The cells decreased proinflammatory cytokines and upregulated anti-inflammatory cytokines and induced Tregs. Therefore, our study suggests that the use of human BM-, AD-, and CB-MSCs could be an effective therapeutic approach for RA.

UR - http://www.scopus.com/inward/record.url?scp=84973149426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973149426&partnerID=8YFLogxK

U2 - 10.3727/096368915X687949

DO - 10.3727/096368915X687949

M3 - Article

C2 - 25853338

AN - SCOPUS:84973149426

VL - 25

SP - 1057

EP - 1072

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 6

ER -